CD2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD2 mouse mAb against MOLT4 (1), MCF-7 (2), L1210 (3), U937 (4), and NIH3T3 (5) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using CD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using CD2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues using CD2 mouse mAb with DAB staining.    

  
  

CD2 Antibody Background

CD2. also known as LFA-2 (lymphocyte function-associated antigen 2), is a 50-55 kDa cell surface glycoprotein belonging to the immunoglobulin (Ig) superfamily. It is primarily expressed on T lymphocytes, natural killer (NK) cells, and thymocytes. Discovered in the early 1980s, CD2 plays a critical role in mediating cell-cell interactions in the immune system. Its primary ligand is LFA-3 (CD58) in humans and CD48 in rodents, facilitating adhesion between T cells and antigen-presenting cells (APCs) or target cells. This interaction is essential for T-cell activation, cytotoxicity, and immune synapse formation.

CD2 antibodies, such as OKT11 and Leu-5b, have been widely used in research and diagnostics. They are employed to study T-cell development, activation, and adhesion mechanisms. In flow cytometry, anti-CD2 antibodies help identify and isolate T-cell subsets. Functionally, some CD2 antibodies act as agonists or antagonists, modulating T-cell responses by either enhancing or blocking CD2-ligand interactions. Early studies revealed that CD2 signaling can synergize with T-cell receptor (TCR) signals to amplify activation or, in certain contexts, induce anergy.

Therapeutically, CD2-targeting strategies have been explored in autoimmune diseases and transplantation. For example, alefacept, a fusion protein targeting CD2. was once used to treat psoriasis by depleting pathogenic T cells. Despite its reduced clinical use today, CD2 remains a key molecule in understanding adaptive immunity and developing immunomodulatory therapies. Research continues to explore its role in infectious diseases, cancer immunotherapy, and immune regulation.